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Obesity is one of the most common medical problems worldwide and a 
risk factor for illnesses such as hypertension, diabetes, degenerative 
arthritis and myocardial infarction.  It is a cause of significant morbidity 
and mortality and generates great social and financial costs.1 WHO’s 
latest projections indicate that globally in 2005, approximately 1.6 
billion adults were overweight and that at least 400 million adults were 
obese.2  Weight loss medications may be appropriate for use in selected 
patients who meet the definition of obesity or who are overweight with 
comorbid conditions.  Medications are formulated to reduce energy 
intake, increase energy output or decrease the absorption of nutrients.  
Drugs cannot replace diet, exercise and lifestyle modification, which 
remain the cornerstones of obesity treatment.1
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both require appropriate and effective 
management by suitably trained members of 
a multidisciplinary team.3  In Malta, 35%  of 
children aged between 7 and 11 years are 
overweight.4
The National Institute for Clinical 
Excellence (NICE) considers people to have 
morbid obesity if: 
• they have a Body Mass Index (BMI) of 40 
kg/m2 or more or 
• they have a BMI of between 35 kg/m2 
and 40 kg/m2 and other significant 
disease (for example, diabetes, high 
blood pressure) that may be improved if 
they lose weight .5
The recognition of the health 
consequences of overweight and obesity, 
the benefits of modest weight loss and the 
frequent failure of lifestyle interventions 
for both weight loss and weight loss 
maintenance, has led to the search for 
effective pharmaceutical anti-obesity 
treatments. 3
The initial treatment of obesity should 
focus on a diet and exercise program that 
has been individualized to the patient’s 
lifestyle and physical needs.  Behavioural 
therapy should be implemented as an 
adjunct to this program.6
Anti-obesity drug therapy is often useful 
as an adjunct for patients who cannot 
achieve sufficient weight loss through 
lifestyle and behavioural modification.3 A 
useful medication for obesity treatment 
must:
• be effective for body weight reduction 
and result in overweight-dependent 
conditions improvement;
• have long-term efficacy and safety;
• be related to tolerable or transitory side 
effects;
• not be addictive;
• have a known mechanism of action;
• be reasonably affordable. 7
Anti-obesity drugs are classified 
on the basis of their mechanism of 
action – appetite suppression, altered 
nutrient absorption, or increased energy 
expenditure.6 
Appetite	suppression
Sibutramine is a norepinephrine and 
serotonin reuptake inhibitor which does 
not stimulate secretion of serotonin.  
The drug produces weight loss by two 
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mechanisms: sibutramine’s central action 
on neurotransmitters results in early 
satiety with reported 20% reduction in 
food intake.  Secondly, sympathetically 
mediated thermogenesis maintains original 
Basal Metabolic Rate which usually falls as 
weight is lost.7 Two studies have looked at 
the incidence of valvular heart disease and 
essentially did not report any difference 
between patients on sibutramine or 
placebo.  Sibutramine 10 or 15 mg provided 
significantly greater weight loss than 
dietary advice alone in a 1-year study of 
485 patients with a BMI of 27 to 40kg/m2. 6 
The National Institute of Clinical 
Excellence reported in 2001 that randomised 
controlled trials found that sibutramine 
produced a dose-related weight loss when 
given in the range 5 – 30mg/day, with an 
optimal dose of 10 – 15 mg/day.  Mean 
weight loss was greater with sibutramine 
than with placebo, on average by about 3 
kg at 8 weeks, between 4 and 9 kg at 24 
weeks and between 4 and 5 kg at 1 year.  
People who had lost weight on sibutramine 
were more likely to maintain the loss when 
sibutramine use was extended than were 
those who were randomised to diet and 
exercise alone.  Retrospective subgroup 
analysis found no statistically significant 
differences between men and women, or 
between ethnic groups in the effects of 
sibutramine treatment. 9
Adverse effects attributed to 
sibutramine include headache, insomnia, 
constipation and dry mouth.  Increases 
in blood pressure and pulse rate may also 
occur.  Patients with cardiac conditions 
should be given this drug with caution.  
The manufacturer advises against giving 
sibutramine to patients with a history of 
coronary artery disease, congestive heart 
failure, arrhythmias or stroke. 10
Altered	nutrient	absorption
Orlistat reduces the systemic absorption 
of dietary fat by potently and irreversibly 
inhibiting gastric and pancreatic lipases. 
These enzymes catalise hydrolytic removal 
of triglycerides fatty acids and produce free 
fatty acids and monoglycerides.6 Orlistat 
binds irreversibly to lipase active sites 
throught covalent binding. 8 By blocking 
these enzymes, triglycerides in dietary fat 
cannot be metabolized into absorbable 
free fatty acids and monoglycerols, and 
thus are excreted in the faeces. 6 Studies 
have shown weight loss of 8.5% at one 
year compared with 5.4 % for placebo.1  
A study looking specifically at the effect 
of orlistat on obese adults with coronary 
heart disease risk factors (type 2 diabetes, 
hypercholesterolaemia or hypertension) 
found that more orlistat-treated patients 
than placebo recipients maintained a weight 
loss of > or equal to 5%.  However, for 
a weight loss of > or equal to 10% there 
was no statistical difference between the 
placebo and treated groups. 11 The view that 
orlistat may be beneficial in patients with 
comorbid conditions related to obesity, 
such as diabetes and hyperlipidaemia is 
supported in several recent reviews.  One 
review noted that in some long-term 
studies, orlistat-treated patients had 
 Orlistat	 Sibutramine	 Rimonabant
Presentation	 120mg hard capsules 10mg and 5mg hard capsules 20mg film-coated tablets
Clinical	Indications Treatment of obese patients with  As an adjunct to diet and exercise for the treatment of obese patients
 a body mass index (BMI) greater  (BMI ≥ 30 kg/m2), or overweight patients (BMI > 27 kg/m2) with
 or equal to 30 kg/m2, or overweight  associated risk factor(s), such as type 2 diabetes or dyslipidaemia.
 patients (BMI ≥ 28 kg/m2) with 
 associated risk factors, in 
 conjunction with a mildly 
 hypocaloric diet. 
Adult	Dose One 120 mg capsule taken with  One capsule of 10 mg swallowed One 20 mg tablet daily
 water immediately before, during  whole, once daily, in the morning,  to be taken in the morning
 or up to one hour after each main  with liquid. The capsule can be before breakfast. 
 meal. If a meal is missed or contains  taken with or without food.
 no fat, the dose of orlistat should  In those patients with an
 be omitted.  inadequate response to 10mg 
  (defined as less than 2 kg weight loss 
  after four weeks treatment), the dose 
  may be increased to one capsule of 
  15mg once daily, provided that the 
  10mg dose was well tolerated. 
Interactions Ciclosporin CYP3A4	inhibitors	e.g. ketoconazole, itraconazole, ritonavir, 
 Acarbose telithromycin, clarithromycin, erythromycin and ciclosporin. 
 Fat soluble vitamins CYP3A4	inducers e.g. rifampicin, phenytoin, Phenobarbital,
 Oral anticoagulants carbamazepine and dexamethasone. 
 Amiodarone Drugs which raise serotonin levels in the brain 
  Simultaneous use of two SSRIs or an SSRI 
  with certain antimigraine drugs or with certain opioids
Table	1:	Comparison	of	drugs	licensed	for	the	treatment	of	obesity	10,14,15	 	 	
34          Journal of the Malta College of Pharmacy Practice      Issue 12 Winter 2007
moderate decreases in diastolic blood 
pressure, insulin levels while fasting, and 
total cholesterol and LDL cholesterol, with 
a small cholesterol-lowering effect that was 
independent of weight loss. 11  
Side effects of orlistat include 
steatorrhea, flatus, faecal incontinence 
and oily spotting.  These effects are more 
dramatic with the consumption of fatty 
foods and may contribute to weight loss 
by discouraging dietary indiscretion.  
In two randomized controlled studies, 
gastrointestinal side effects were considered 
mild to moderate and improved in the 
second year of treatment. 1
Increased	energy	expenditure
Agents that increase energy expenditure 
are scarce.  The search for a thermogenic 
medication that has a tolerable side 
effect profile has yielded few drugs, and 
none is recommended for weight loss 
treatment.1 Ephedrine and the xanthines, 
such as caffeine and theophylline, increase 
metabolic rate.  Studies have demonstrated 
their efficacy as short-term weight loss 
medications, but the risk of cardiac 
complications from hypertension, increased 
heart rate, increased myocardial oxygen 
consumption and increased cardiac output 
limit their clinical use.1
Other	drugs
Rimonabant
Rimonabant was the first selective 
cannabinoid-1 receptor blocker to enter 
clinical trials.  In genetic and diet-
induced obesity, rimonabant, reduces 
overactivation of the central and peripheral 
endocannabinoid system and prevents 
weight gain and associated metabolic 
disorders.12 The results of a randomized, 
double-blind, placebo-controlled 2-year 
multicenter study suggest that 20mg per 
day of rimonabant is effective in reducing 
body weight and waist circumference, 
while also favourably affecting several 
cardiometabolic risk factors.12  Most of 
these effects were dose-dependent.  The 
RIO-North America trial concluded that 
compared with patients who received 
placebo, patients who received 20mg of 
rimonabant had favourable changes in 
levels of HDL cholesterol, triglycerides, 
and fasting insulin that appeared to 
be approximately twice that expected 
from the achieved weight loss alone, 
suggesting a direct pharmacological 
effect of rimonabant on glucose and 
lipid metabolism beyond the weight loss 
achieved.13  
In placebo-controlled studies, the 
discontinuation rate due to adverse 
reactions was 15.7 % for patients receiving 
rimonabant and the most common adverse 
reactions resulting in discontinuation 
were: nausea, mood alteration with 
depressive symptoms, depressive disorders, 
anxiety and dizziness.14
Over	the	counter	(OTC)	products
A number of OTC products are 
advertised as treatments for weight 
loss.  Patients and physicians should be 
aware that such products are packaged 
in uncertain dosages and are usually of 
uncertain potency and purity.  This in 
turn can lead to unpredictable therapeutic 
and adverse effects.  Thus, the treatment 
of choice for patients with a low risk of 
obesity is not OTC products but dietary 
intervention accompanied by exercise and 
behavioural modification.
Treatment	considerations
Most antiobesity medications produced 
5% to 10% weight loss in clinical trials, 
which is likely to be of significant medical 
benefit even if the patient has not reached 
his or her desirable body weight.  Obesity 
is a chronic disease, as evidenced by the 
high likelihood of weight regain, and 
consequently a long-term approach to 
treatment is needed. 6
Clinicians must learn to recognize 
treatment failure and alter the drug 
therapy regimen.  Patients who do not 
lose at least 4lbs during the first 4 to 8 
weeks of therapy should be considered 
non-responders to that medication.  In 
this situation, the medication should be 
stopped and another anti-obesity drug 
should be considered.  Table 1 gives a 
comparison of drugs licensed for the 
treatment of obesity.  Once a patient has 
lost a significant amount of weight, it 
becomes important to sustain the weight 
loss. 6
• The aims of treatment for overweight and obesity should be modest weight loss 
maintained for the long term, with treatment methods and goals being decided 
for each individual after careful assessment of the degree of overweight and any 
associated co-morbid conditions.
• The first-line strategy is a combination of supervised diet, exercise and behaviour 
modification. 
• Anti-obesity drugs may be used in adult patients at medical risk from obesity (BMI 
30 or greater), or overweight patients with established co-morbidities (BMI 27) if 
the drug license permits.
• Not all obese patients respond to drug therapy.  An anti-obesity drug should 
therefore be prescribed for no longer than 12 weeks in the first instance and weight 
loss should then be measured.  The drug treatment should be stopped in those 
obese patients who have not achieved a 5% weight reduction after 12 weeks of 
treatment.  If a 5% weight loss is attained then the drug may be continued beyond 
this initial period, provided body weight is continually monitored and weight is not 
regained.  
• The duration of treatment with an anti-obesity drug must never exceed the time 
period recommended by the product license of the drug. 
• Prescribers of anti-obesity drugs must be aware of their possible adverse actions.  
When assessing the suitability of a patient for drug treatment, it is important to 
consider the risk/benefit ratio, remembering that drug therapy is not without risk.
• All obese patients receiving drug therapy should be given regular review.
Practice	Points	16
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Conclusion	
Obesity is recognized as an epidemic 
condition that affects populations 
worldwide.  Therefore, the need to 
improve the quality and efficacy of 
therapeutics has emerged.  The core to 
current obesity management is based on 
specific behavioural therapies aiming to 
change eating habits and raise energy 
expenditure, nutritional counseling to 
lower the intake of calories, particularly 
fat as well as increased daily physical 
activities.  
Pharmacological management is 
seen as an additional tool to this basic 
therapy in those patients where dietary 
and lifestyle modifications have proved 
unsuccessful.  The thoughtful use of 
medications for the management of 
obesity can be valuable for many patients, 
however, no medication alone will solve 
the problem of obesity and no medication 
should be used as a substitute for the 
development of healthier adults.
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